HCV / Hepatitis

A company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b (HBV).

A congressional subcommittee aims at reducing HIV-related budget items by over half a billion dollars.

In a major breakthrough, Gilead’s remdesivir (Veklury) becomes the first COVID-19 antiviral to be FDA-approved for patients with severe renal disease.

Among people living with hepatitis C virus (HCV), viral clearance was only 34%. Cure rates were even lower among uninsured persons younger than 40.

The investigational therapy from Gilead showed effectiveness and safety at 96 weeks.

Liver education has been void in the school systems and children and young adults stand to gain enormously when provided with awareness around this essential organ.

Clinicians should consider adenovirus testing in pediatric patients with hepatitis of unknown etiology. Here is an update on the incidence rates and lab diagnostics associated with identifying the virus.

Biopharmaceutical company, Vaccitech, has developed its VTP-300 vaccine, and is presenting a poster demonstrating positive early data at the ongoing European Association for the Study of the Liver (EASL) Congress 2023.

Infants age 2 to 6 months who were perinatally exposed to hepatitis C infection should be tested with a single HCV RNA test for optimal results, a recent study suggests.

While African American/Black participants were less likely to meet treatment criteria, treatment receipt did not significantly differ by race, indicating equitable access to treatment.

The agency said that in recent days a few more suppliers initiated a voluntary recall of additional select packages sold at national stores.

The first patient was dosed for this open-label trial.

With an estimated 30% of Americans living with a tattoo, the federal agency has developed guidance designed to give manufacturers information and resources to prevent potential health issues.

The new guidelines for the first time offer guidance for patients who are not fully adherent to direct-acting antivirals.

In a guest commentary, Thelma Thiel, RN, Cofounder of The Liver Health Initiative provides a personal perspective on her son’s liver issues and the importance of why everyone should get tested for HCV.

Due to worsening headaches and unrevealing cross-sectional imaging and ascites fluid analyses, this patient's differential evolved toward a central nervous system source.

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.

Cherokee Nation Health Services in Oklahoma found that 61% of patients diagnosed with HCV initiated care during the first five years of a program to eliminate HCV.

A new study looked at the risk of hepatitis B and C as a result of exposure from such procedures.

Previously estimated 0.32% HBV prevalence in the US is closer to 0.55%, according to new modeling study that accounts for immigrant population.

From outbreaks to breakthroughs, these are the biggest infectious disease headlines from the past week.

A new documentary looks at dealing with the condition long-term, and serves as a microcosm for how people suffer through chronic conditions and diseases, and may not get the help they need.

Atea Pharmaceutical’s investigational therapy, bemnifosbuvir, is in a phase 3 trial for the former and phase 2 for the latter.

European medical committee offers favorable opinion for people with all forms of renal impairment including those on dialysis.

The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.

An antibiotic development stakeholder believes the current paradigm needs to be changed in order for more antibiotics to get FDA approved and reduce multidrug-resistance.

This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Sulbactam-durlobactam (Xacduro) was developed to treat the troublesome Acinetobacter baumannii pathogen that can be associated with bacterial pneumonia.

Screening and treating immigrants for hepatitis C virus infection may be instrumental to eliminating the disease in Canada.

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.